Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

3 days ago

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further analysis and discussions on …

Read Entire Article

Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial

Related

AI Agents in DeFi: User Control Must Be ‘Non-Negotiable,’ CE...

FBI Cracks $290M Crypto Scam—Trade Coin Club Exposed

President Trump Declares End to Biden’s Crypto War, Pledges ...

Ethereum rollback deemed 'technically intractable' amid Bybi...

Mapping XRP’s price targets – Is NOW the right time to buy?

BRICS Discusses Alternative Payment Platforms to Bypass West...

Breaking: Could Bybit’s $1.4B Hack Have Been Stopped? Ledger...

Robert Kiyosaki: Market Collapse Has Begun—Bitcoin’s Comebac...

Popular

🚨 BITCOIN: LAST WARNING!!!!!!!!!!!!🚨 [this happened before]

XRP Price Analysis: Crypto Traders Brace for a Wild Ride as ...

Bulgaria's anti-euro protesters try to storm EU mission buil...

1,000 Bulgarian nationalists protest against government plan...

Gold gains sheen as RBI dips into forex reserves

iYield | The Best Free Platform To Track All Your Crypto & D...